Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae112 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Sara Ahmadi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Thyroid Nodule. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Context
Molecular testing can refine the risk of malignancy in thyroid nodules with indeterminate cytology to decrease unnecessary diagnostic surgery.
Objective
This study was performed to evaluate the outcomes of cytologically indeterminate thyroid nodules managed with Afirma genomic sequencing classifier (GSC) testing.
Methods
Adult patients who underwent a biopsy at 3 major academic centers between July 2017 and June 2021 with Bethesda III or IV cytology were included. All patients had surgery or minimum follow-up of 1 year ultrasound surveillance. The primary outcomes were the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of GSC in Bethesda III and IV nodules.
Results
The median nodule size of the 834 indeterminate nodules was 2.1 cm and the median follow-up was 23 months. GSC sensitivity, specificity, PPV, and NPV across all institutions were 95%, 81%, 50%, and 99% for Bethesda III nodules and 94%, 82%, 65%, and 98% for Bethesda IV nodules, respectively. The overall false-negative rate was 2%. The NPV of GSC in thyroid nodules with oncocytic predominance was 100% in Bethesda III nodules and 98% in Bethesda IV nodules. However, the PPV of oncocytic nodules was low (17% in Bethesda III nodules and 45% in Bethesda IV nodules). Only 22% of thyroid nodules with benign GSC results grew during surveillance.
Conclusion
GSC is a key tool for managing patients with indeterminate cytology, including the higher-risk Bethesda IV category. GSC-benign thyroid nodules can be observed similarly to thyroid nodules with benign cytology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Department of Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.
ORCID-Profile: Anupam Kotwal, Athanasios Bikas, Whitney Goldner, Anery Patel, Elena G Hughes, Xochitl Longstaff, Michael W Yeh, Masha J Livhits
Zitieren
APA
Ahmadi, S., Kotwal, A., Bikas, A., Xiang, P., Goldner, W., Patel, A., Hughes, E. G., Longstaff, X., Yeh, M. W., & Livhits, M. J. (2024). Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae112
Vancouver
Ahmadi S, Kotwal A, Bikas A, Xiang P, Goldner W, Patel A, et al. Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae112
BibTeX
@article{Ahmadi2024,
author = {Ahmadi, Sara and Kotwal, Anupam and Bikas, Athanasios and Xiang, Pingping and Goldner, Whitney and Patel, Anery and Hughes, Elena G and Longstaff, Xochitl and Yeh, Michael W and Livhits, Masha J},
title = {Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae112}
}
EUVIMED